| Literature DB >> 29731005 |
Rudolf Valenta1, Alexander Karaulov2, Verena Niederberger3, Pia Gattinger4, Marianne van Hage5, Sabine Flicker4, Birgit Linhart4, Raffaela Campana4, Margarete Focke-Tejkl4, Mirela Curin4, Julia Eckl-Dorna3, Christian Lupinek4, Yvonne Resch-Marat4, Susanne Vrtala4, Irene Mittermann4, Victoria Garib6, Musa Khaitov7, Peter Valent8, Winfried F Pickl9.
Abstract
Immunoglobulin E (IgE)-associated allergy is the most common immune disorder. More than 30% of the population suffer from symptoms of allergy which are often severe, disabling, and life threatening such as asthma and anaphylaxis. Population-based birth cohort studies show that up to 60% of the world population exhibit IgE sensitization to allergens, of which most are protein antigens. Thirty years ago the first allergen-encoding cDNAs have been isolated. In the meantime, the structures of most of the allergens relevant for disease in humans have been solved. Here we provide an update regarding what has been learned through the use of defined allergen molecules (i.e., molecular allergology) and about mechanisms of allergic disease in humans. We focus on new insights gained regarding the process of sensitization to allergens, allergen-specific secondary immune responses, and mechanisms underlying allergic inflammation and discuss open questions. We then show how molecular forms of diagnosis and specific immunotherapy are currently revolutionizing diagnosis and treatment of allergic patients and how allergen-specific approaches may be used for the preventive eradication of allergy.Entities:
Keywords: Allergen; Allergy; Immunoglobulin E; Molecular allergology; Recombinant allergen
Mesh:
Substances:
Year: 2018 PMID: 29731005 DOI: 10.1016/bs.ai.2018.03.002
Source DB: PubMed Journal: Adv Immunol ISSN: 0065-2776 Impact factor: 3.543